Koen Sandra

Koen Sandra is the editor of “Biopharmaceutical Perspectives”. He is CEO at RIC group and visiting professor at Ghent University. He is also a member of LCGC Europe’s editorial advisory board.

Articles by Koen Sandra

BASS Figure 3-1.jpg

With the top-selling mAbs evolving out of patent there has been a growing interest in the development of biosimilars. In demonstrating comparability to the originator product, biosimilar developers are confronted with an enormous analytical challenge. This article presents a selection of state-of-the-art analytical tools for mAb characterisation and comparability assessment.